| dc.contributor.author | Henricson, Martin | |
| dc.date.accessioned | 2015-05-29T14:17:06Z | |
| dc.date.available | 2015-05-29T14:17:06Z | |
| dc.date.issued | 2015-05-29 | |
| dc.identifier.uri | http://hdl.handle.net/2077/39194 | |
| dc.description.abstract | Master thesis, Programme in Medicine. TITLE: Osteoporosis treatment and fracture risk associated with castration in prostate cancer. Background
Approximately
10,000
people
are
diagnosed
with
prostate
cancer
every
year
in
Sweden.
For
those
with
a
metastasised
disease
castration
through
orchiectomy
or
chemically
by
LHRH
agonist
might
be
an
option.
It
has
previously
been
shown
that
this
treatment
increases
the
risk
of
osteoporosis
and
fractures
for
this
group
of
patients.
This
paper
is
a
retrospective
study
of
medical
records
regarding
the
prevention
and
treatment
of
osteoporosis
associated
with
castration
through
LHRH
agonist
and
orciectomy
in
patients
with
prostate
cancer.
Aim
To
investigate
the
extent
to
which
patients
at
Sahlgrenska
hospital
got
fractures
and
which
patients
are
treated
for
osteoporosis
in
connection
with
castration
treatment
through
LHRH
agonist
or
orchiectomy.
To
see
how
osteoporosis
is
diagnosed
and
treated
and
whether
there
are
any
predispositional
factors
that
could
help
identify
patients
that
would
benefit
from
osteoporosis
prophylaxis.
Method
Studying
the
medical
records
of
316
patients
who
underwent
castration
treatment
through
LHRH
agonist
or
orchiectomy
at
Sahlgrenska
in
2007
or
2008.
The
amount
and
type
of
fractures,
whether
the
patients
have
undergone
examinations
such
as
bone
densitometry
scans
and/or
bone
scintigraphy
as
well
as
the
patients’
overall
health
and
use
of
medications.
Result
Osteoporosis
was
prevented
or
treated
in
connection
with
castration
treatment
in
just
seven
out
of
316
cases
at
Sahlgrenska
in
2007
and
2008.
The
risk
of
fracture
after
castration
is
considerably
higher
than
in
the
normal
population
in
the
corresponding
age
group,
24,9
per
1000
person
years
in
this
material
compared
to
9
per
1000
person
years.
At
present
no
specific
guidelines
for
treatment
and
prevention
of
osteoporosis
in
connection
with
castration
are
in
place
at
Sahlgrenska.
Conclusion
There
is
scope
to
co-‐ordinate
the
criteria
for
prevention
of
osteoporosis
and
thereby
an
opportunity
to
lower
the
fracture
rate
in
those
patients.
As
this
is
a
retrospective
study
of
medical
records
with
relatively
limited
material
more
research
could
be
carried
out
in
this
area. | sv |
| dc.language.iso | swe | sv |
| dc.subject | Prostate cancer | sv |
| dc.subject | GhRh-agonist | sv |
| dc.subject | Osteoporosis | sv |
| dc.title | Osteoporosbehandling och frakturrisk i samband med kastration vid prostatacancer | sv |
| dc.type | Text | |
| dc.setspec.uppsok | Medicine | |
| dc.contributor.department | University of Gothenburg / Institute of Medicine | eng |
| dc.contributor.department | Göteborgs universitet / Institutionen för medicin | swe |
| dc.type.degree | Student essay | |
